Cisplatin‐stimulated murine bone marrow‐derived macrophages secrete oncostatin M
- 1 October 1997
- journal article
- Published by Wiley in Immunology & Cell Biology
- Vol. 75 (5) , 492-496
- https://doi.org/10.1038/icb.1997.76
Abstract
Cisplatin (CP), a widely used anticancer drug activates cells of the immune system to a tumoricidal state, and thus functions as a potent biological response modifier. Expression of oncostatin M (OSM), a novel cytokine having a growth regulatory effect, was studied in bone marrow-derived macrophages treated with cisplatin. Supematants from CP-stimulated macrophages were found to be cytostatic for OSM-sensitive A375 melanoma cells. Immunoblot analysis with anti-OSM antibody revealed that expression of OSM in macrophages upon CP stimulation is a rapid process and within 30 min of CP treatment, a significant amount of OSM is secreted into the culture supernatant. These results therefore indicate that CP can stimulate murine bone marrow-derived macrophages to produce OSM which can be implicated as one of the cytostatic/cytocidal factors in the antitumour action of cisplatin-stimulated macrophages.Keywords
This publication has 17 references indexed in Scilit:
- Oncostatin MProgress in Growth Factor Research, 1992
- Production of reactive nitrogen intermediates by bone marrow-derived macrophages on treatment with cisplatin in vitroClinical and Experimental Immunology, 1992
- Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6.Proceedings of the National Academy of Sciences, 1991
- Production of interleukin-1 and tumor necrosis factor by bone marrow-derived macrophages: effect of cisplatin and lipopolysaccharideImmunology Letters, 1991
- Stimulation of protein tyrosine phosphorylation by the B-lymphocyte antigen receptorNature, 1990
- Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin.Proceedings of the National Academy of Sciences, 1988
- Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2.Proceedings of the National Academy of Sciences, 1988
- Release of cytolytic factor(s) by murine macrophages in vitro on treatment with cis-PlatinInternational Journal of Immunopharmacology, 1986
- Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in VitroScience, 1985